创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

丁嘉欣, 杨婷婷, 江振洲, 张陆勇. 胆汁淤积性肝病潜在治疗药物研究进展[J]. 药学进展, 2018, 42(10): 772-779.
引用本文: 丁嘉欣, 杨婷婷, 江振洲, 张陆勇. 胆汁淤积性肝病潜在治疗药物研究进展[J]. 药学进展, 2018, 42(10): 772-779.
DING Jiaxin, YANG Tingting, JIANG Zhenzhou, ZHANG Luyong. Research Progress in Potential Therapeutic Drugs for Cholestatic Liver Diseases[J]. Progress in Pharmaceutical Sciences, 2018, 42(10): 772-779.
Citation: DING Jiaxin, YANG Tingting, JIANG Zhenzhou, ZHANG Luyong. Research Progress in Potential Therapeutic Drugs for Cholestatic Liver Diseases[J]. Progress in Pharmaceutical Sciences, 2018, 42(10): 772-779.

胆汁淤积性肝病潜在治疗药物研究进展

Research Progress in Potential Therapeutic Drugs for Cholestatic Liver Diseases

  • 摘要: 胆汁淤积性肝损伤的发生伴随着胆汁酸稳态的失衡,蓄积的胆汁酸是肝损伤的直接诱因。胆汁酸转运蛋白与核受体通过调控胆汁酸水平维持机体胆汁酸稳态。从胆汁酸转运蛋白与核受体出发,系统介绍胆汁淤积性肝脏疾病治疗药物的最新进展,为胆汁淤积性肝损伤的治疗药物研发提供参考。

     

    Abstract: Cholestatic liver injury is usually accompanied by disordered homeostasis of bile acid, and the accumulation of bile acid is the direct cause of liver injury. Bile acid transporters and nuclear receptors maintain bile acid homeostasis by regulating the level of bile acid. This article systematically introduced the latest progress in the therapeutic drugs for cholestatic liver diseases from the perspectives of bile acid transporters and nuclear receptor, so as to provide reference for the development of related therapeutic drugs.

     

/

返回文章
返回